FIBROSIS STAGE

F1-F2 (minimal fibrosis)

A Fibrosis Stage of F1–F2 (minimal fibrosis) indicates that your liver shows early signs of scarring, but the damage is still mild and potentially reversible. This stage represents a transition between minimal (F1) and moderate (F2) fibrosis, meaning that while some fibrous tissue is forming as a response to liver injury or inflammation, the overall liver structure and function remain well preserved. At this point, it’s important to address and manage the underlying cause—such as fatty liver disease (MASLD/NASH), viral hepatitis, alcohol use, or metabolic conditions—to prevent progression to more advanced fibrosis. Many people at this stage can stabilize or even improve their liver health through targeted lifestyle changes: maintaining a healthy weight, following a balanced Mediterranean-style diet, engaging in regular physical activity, avoiding alcohol, and controlling blood sugar, cholesterol, and blood pressure. Your healthcare provider may recommend periodic re-testing—for example, with a repeat FibroTest®, FibroScan®, or liver enzyme panel—to monitor for improvement or progression. Overall, F1–F2 fibrosis is a manageable and early stage, where proactive steps can make a meaningful difference in long-term liver health.

Fibrosis Stage estimates how much scarring (fibrosis) is present in your liver by converting a FibroTest® score (f)—a composite of routine blood markers plus age/sex—into the familiar METAVIR staging system (F0–F4). It’s used to triage risk, decide on next tests (e.g., FibroScan®/elastography), guide treatment intensity, and monitor change over time, often without needing a biopsy.


How to read your result

Your FibroTest score (f) falls into one of the ranges below, which map to a METAVIR stage. “Bridged” categories (e.g., F1–F2) indicate an intermediate probability between two adjacent stages.

FibroTest (f) → METAVIR stage

  • f ≥ 0.00 and f ≤ 0.21: F0 (no fibrosis)

  • f > 0.21 and f ≤ 0.27: F0–F1 (no fibrosis)

  • f > 0.27 and f ≤ 0.31: F1 (minimal fibrosis)

  • f > 0.31 and f ≤ 0.48: F1–F2 (minimal fibrosis)

  • f > 0.48 and f ≤ 0.58: F2 (moderate fibrosis)

  • f > 0.58 and f ≤ 0.72: F3 (advanced fibrosis)

  • f > 0.72 and f ≤ 0.74: F3–F4 (advanced fibrosis)

  • f > 0.74 and f ≤ 1.00: F4 (severe fibrosis / cirrhosis)

Always interpret your number using the reference printed on your report and in clinical context.


What each stage generally means

F0 (no fibrosis)

  • What it means: No measurable scarring. Liver architecture is preserved.

  • Typical next steps: Maintain liver-healthy habits; periodic reassessment based on risk (e.g., 1–3 years).

F0–F1 (no fibrosis) and F1 (minimal fibrosis)

  • What it means: Little to no scarring (F0–F1) or early/minimal scarring (F1).

  • Implications: Excellent outlook if risk factors are addressed.

  • Follow-up: Lifestyle optimization; treat the cause (e.g., viral hepatitis therapy, alcohol cessation, metabolic care). Re-check at intervals set by your clinician.

F1–F2 (minimal → moderate fibrosis)

  • What it means: Transition zone—some patients behave like F1, others like F2.

  • Implications: Rising risk of progression if the underlying disease persists.

  • Follow-up: Consider confirmatory testing (e.g., FibroScan®), closer monitoring, and proactive treatment of the cause.

F2 (moderate fibrosis)

  • What it means: Clinically meaningful scarring; progression risk is higher.

  • Implications: Intensify management of the underlying condition (MASLD/NASH, viral hepatitis, alcohol-related, etc.).

  • Follow-up: Non-invasive fibrosis assessment and labs at regular intervals; consider hepatology referral.

F3 (advanced fibrosis) and F3–F4 (advanced → severe)

  • What it means: Extensive scarring with architectural distortion; one step from cirrhosis (F4).

  • Implications: Elevated risk for complications; requires specialist involvement.

  • Follow-up: Confirm with elastography/imaging; manage portal hypertension risks; aggressive cause-directed therapy.

F4 (severe fibrosis / cirrhosis)

  • What it means: Cirrhosis—extensive scarring and nodule formation.

  • Implications: Assess for decompensation risks and hepatocellular carcinoma (HCC) surveillance per guidelines.

  • Follow-up: Ongoing hepatology care, vaccination review (HAV/HBV if non-immune), nutrition support, and complication screening.


When scores may be misleading

Certain factors can artificially raise or lower components of the FibroTest and shift the stage:

  • Acute hepatitis or recent flare (spikes AST/ALT, bilirubin)

  • Cholestasis, Gilbert syndrome, hemolysis

  • Severe inflammation or intercurrent illness

  • Recent heavy alcohol use

  • Medications/supplements affecting liver enzymes or lipids
    If any apply, clinicians often repeat testing after stabilization or confirm with elastography.


What you can do (at any stage)

  • Treat the cause: antiviral therapy for HBV/HCV when indicated; alcohol cessation; structured care for MASLD/NASH (weight loss target 7–10% if overweight/obese; diabetes control; lipid management).

  • Lifestyle: Mediterranean-style eating pattern; limit fructose-sweetened beverages and ultra-processed foods; regular aerobic + resistance exercise; sleep and stress management.

  • Risk reduction: Vaccinate (HAV/HBV if non-immune), review meds for hepatotoxicity, manage cardiovascular and renal risks.

  • Monitoring: Follow your personalized schedule for labs and non-invasive fibrosis tests; escalate assessment if results worsen or symptoms change.


Key takeaways

  • Your FibroTest score maps to METAVIR to communicate fibrosis severity from F0 (none) to F4 (cirrhosis).

  • Border zones (F0–F1, F1–F2, F3–F4) reflect intermediate probabilities—often prompting confirmatory elastography.

  • Use the stage to guide action: maintain liver health at low stages; intensify treatment and monitoring at moderate/advanced stages; engage hepatology at F3–F4.

  • Results work best in context—paired with clinical history, imaging, and follow-up over time.

FIBROSIS STAGE
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond FIBROSIS STAGE — 10,000+ markers explained
One FIBROSIS STAGE result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro